New diagnostic and therapeutic tools
against multidrug resistant tumours

Scientific publications

Please, add the following sentence for any scientific publication related to the STRATAGEM COST Action:

This work was performed within the framework of COST Action CA17104 STRATAGEM -” New diagnostic and therapeutic tools against multidrug resistant tumors”.

After publication of a contribution related to the Stratagem COST Action please send the citation as formatted in the first paper to stratagem.cost@gmail.com

  1. Durante M, Frosini M, Fusi F, Gamberucci A, Chegaev K, Rolando B, Riganti C, Fruttero R, Saponara S. In vitro vascular toxicity assessment of NitDOX, a novel NO-releasing doxorubicin. European Journal of Pharmacology 2020, 880, 173164. doi: 10.1016/j.ejphar.2020.173164
  2. Palmeira A, Sousa E, Köseler A, Sabirli R, Gören T, Türkçüer İ, Kurt Ö, Pinto M, Vasconcelos MH. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection. Pharmaceuticals 2020, 13(6), 132; doi: 10.3390/ph13060132
  3. Dinić J, Efferth T, Garcia-Sosa A, Grahovac J, Padrón J, Pajeva I, Rizzolio F, Saponara S, Spengler G, Tsakovska I. Repurposing old drugs to fight multidrug resistant cancers. Drug Resistance Updates 2020, , 100713. doi: 10.1016/j.drup.2020.100713
  4. Lepeltier E, Rijo P, Rizzolio F, Popovtzer R, Petrikaite V, Assaraf YG, Passirani C. Nanomedicine to Target Multidrug Resistant Tumors. Drug Resistance Updates 2020, 52, 100704. doi: 10.1016/j.drup.2020.100704
  5. Isca V, Sencanski M, Filipovic N, Dos Santos D, Čipak Gašparović A, Saraíva L, Afonso C, Rijo P, García-Sosa A. Activity to Breast Cancer Cell Lines of Different Malignancy and Predicted Interaction with Protein Kinase C Isoforms of Royleanones. International Journal of Molecular Sciences 2020, 21, 3671. doi: 10.3390/ijms21103671
  6. Isca V, Ferreira R, Garcia C, Monteiro C, Dinic J, Holmstedt S, André V, Pešić M, Dos Santos D, Candeias N, Afonso C, Rijo P. Molecular Docking Studies of Royleanone Diterpenoids from Plectranthus spp. as P-Glycoprotein Inhibitors. ACS Medicinal Chemistry Letters 2020, 11, 839-845. doi: 10.1021/acsmedchemlett.9b00642
  7. Stark M, Silva, TFD, Levin G, Machuqueiro M, Assaraf YG. The Lysosomotropic Activity of Hydrophobic Weak Base Drugs is Mediated via Their Intercalation into the Lysosomal Membrane. Cells 2020, 9, 1082. doi: 10.3390/cells9051082
  8. Fathy Abd-Ellatef GE, Gazzano E, Chirio D, Hamed AR, Belisario DC, Zuddas C, Peira E, Rolando B, Kopecka J, Assem Said Marie M, Sapino S, Ramadan Fahmy S, Gallarate M, Abdel-Hamid AZ, Riganti C. Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells. Pharmaceutics. 2020, 12, E96. doi: 10.3390/pharmaceutics12020096
  9. Dallavalle S, Dobričić V, Lazzarato L, Gazzano E, Machuqueiro M, Pajeva I, Tsakovska I, Zidar N, Fruttero R. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resistance Updates 2020, 50, 100682. doi: 10.1016/j.drup.2020.100682
  10. Kopecka J, Trouillas P, Gašparović AČ, Gazzano E, Assaraf YG, Riganti C. Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. Drug Resistance Updates 2020, 49, 100670. doi: 10.1016/j.drup.2019.100670
  11. Tolios A, De Las Rivas J, Hovig E, Trouillas P, Scorilas A, Mohr T. Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions. Drug Resistance Updates 2020, 48, 100662. doi: 10.1016/j.drup.2019.100662
  12. Andrei L, Kasas S, Ochoa Garrido I, Stanković T, Korsnes MS, Vaclavikovak R, Assaraf YG, Pešić M. Advanced technological tools to study multidrug resistance in cancer. Drug Resistance Updates 2020, 48, 100658. doi: 10.1016/j.drup.2019.100658
  13. Dömötör O, Kiss MA, Gál GT, May NV, Spengler G, Nové M, Gašparović AČ, Frank É, Enyedy ÉA. Solution equilibrium, structural and cytotoxicity studies on Ru(η(6)-p-cymene) and copper complexes of pyrazolyl thiosemicarbazones. Journal of Inorganic Biochemistry 2020, 202, 110883. doi: 10.1016/j.jinorgbio.2019.110883.
  14. Dinić J, Ríos-Luci C, Karpaviciene I, Cikotiene I, Fernandes MX, Pešić M, Padrón JM. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells. Investigational New Drugs 2020, 38, 584-598. doi: 10.1007/s10637-019-00803-6
  15. Vasconcelos MH, Caires HR, Ābols A, Xavier CPR, Linē A. Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance. Drug Resistance Updates 201947, 100647. doi: 10.1016/j.drup.2019.100647
  16. Sarmento-Ribeiro AB, Scorilas A, Gonçalves AC, Efferth T, Trougakos IP. The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resistance Updates 201947, 100646. doi: 10.1016/j.drup.2019.100646
  17. Lazzarato L, Gazzano E, Blangetti M, Fraix A, Sodano F, Picone GM, Fruttero R, Gasco A, Riganti C, Sortino S. Combination of PDT and NOPDT with a Tailored BODIPY Derivative. Antioxidants 20198, E531. doi: 10.3390/antiox8110531
  18. Puerta A, Galán AR, Abdilla R, Demanuele K, Fernandes MX, Bosica G, Padrón JM. Naphthol-derived Betti bases as potential SLC6A14 blockers. Journal of Molecular and Clinical Medicine 2019, 2, 35-40. doi: 10.31083/j.jmcm.2019.02.7181
  19. Gazzano E, Kopecka J, Belisario CD, Costamagna C, Riganti C.  A new LDL-masked liposomal doxorubicin overcomes drug resistance in osteosarcoma. Journal of Molecular and Clinical Medicine 20192, 1-9. doi: 10.31083/j.jmcm.2019.01.6161
  20. Garcia C, Ntungwe E, Rebelo A, Bessa C, Stankovic T, Dinic J, Díaz-Lanza A, Reis CP, Roberto A, Pereira P, Cebola M-J, Saraiva L, Pešić M, Duarte N, Rijo P. Parvifloron D from Plectranthus strigosus: Cytotoxicity screening of Plectranthus spp. extracts. Biomolecules 2019, 9, 616. doi: 10.3390/biom9100616
  21. Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPE, Vasconcelos H. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resistance Updates 2019, 46, 100645. doi: 10.1016/j.drup.2019.100645
  22. Alexa-Stratulat T, Pešić M, Gašparović AČ, Trougakos IP, Riganti C. What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. Drug Resistance Updates 2019, 46, 100643. doi: 10.1016/j.drup.2019.100643
  23. Dinić J, Podolski-Renić A, Jovanović M, Musso L, Tsakovska I, Pajeva I, Dallavalle S, Pešić M. Novel Heat Shock Protein 90 inhibitors suppress P-glycoprotein activity and overcome multidrug resistance in cancer cells. International Journal of Molecular Sciences 201920, 4575. doi: 10.3390/ijms20184575.
  24. Viktorová J, Dobiasová S, Řehořová K, Biedermann D, Káňová  K, Šeborová K, Václavíková R, Valentová K, Ruml T, Křen V, Macek T. Antioxidant, anti-inflammatory, and multidrug resistance modulation activity of silychristin derivatives. Antioxidants 2019, 8, 303. doi: 10.3390/antiox8080303
  25. Podolski-Renić A, Dinić J, Stanković T, Jovanović M, Ramović A, Pustenko A, Žalubovskis R, Pešić M. Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance. European Journal of Pharmaceutical Sciences 2019, 138, 105012. doi: 10.1016/j.ejps.2019.105012
  26. Rodrigues C, Milković L, Tartaro Bujak I, Tomljanović M, Soveral G, Gašparović AČ. Lipid profile and aquaporin expression under oxidative stress in breast cancer cells of different malignancies. Oxidative Medicine and Cellular Longevity 2019, 2019, 2061830. doi: 10.1155/2019/2061830
  27. Gazzano E, Kopecka J, Castella B, Buondonno I, Costamagna C, Riganti C. Novel anthracyclines with enhanced immunogenic effects against drug resistant osteosarcoma cells. Journal of Molecular and Clinical Medicine 2018, 1, 227-236. doi: 10.31083/j.jmcm.2018.04.325001